Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL709569

CC(C)Oc1cc(OCc2cccnc2)cc(-c2nc3cccnc3[nH]2)c1.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 1/20 0.43
GCK P35557 2/20 0.42
GPR132 Q9UNW8 11/20 0.42
HCRTR1 O43613 1/20 0.41
ADAMTS4 O75173 1/20 0.40
ACACB O00763 1/20 0.40
MMP13 P45452 1/20 0.40
POLB P06746 1/20 0.39
HPGD P15428 1/20 0.39
CMKLR2 P46091 1/20 0.39
CMKLR1 Q99788 1/20 0.39
APAF1 O14727 1/20 0.39
PABPC1 P11940 1/20 0.39
CASP6 P55212 1/20 0.39
CASP8 Q14790 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL713011 0.94 GCK (0.44) DHODHGCK
Trifluoroacetic Acid SCHEMBL709188 0.92 GCK (0.39) DHODHGCKGPR132ADAMTS4MMP13
Trifluoroacetic Acid SCHEMBL711040 0.91 DHODH (0.45) DHODHGPR132HCRTR1MMP13CMKLR2
SCHEMBL10206659 0.91 DHODH (0.41) DHODHGCKGPR132HCRTR1ADAMTS4
Trifluoroacetic Acid SCHEMBL720615 0.87 GCK (0.45) GCK
Trifluoroacetic Acid SCHEMBL709921 0.87 GCK (0.43) GCK
Trifluoroacetic Acid SCHEMBL712377 0.86 CHEK2 (0.45) DHODH
Trifluoroacetic Acid SCHEMBL709930 0.86 GCK (0.48) GCK
SCHEMBL709496 0.85 PRMT5 (0.44) GCK
Trifluoroacetic Acid SCHEMBL711107 0.85 GPR132 (0.43) DHODHGPR132ACACBMMP13CMKLR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1940837-B1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2012-11-07 EP disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 US disclosed
EP-1940837-A2 IMIDAZOPYRIDINE COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2008-07-09 EP disclosed
WO-2007028135-A2 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS GCK, GCKR, KHK DHODH 910/4885GCK 1/4885GPR132 2062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.